Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma

Cancer Immunology, Immunotherapy

Volumn 57, Issue 7, 2008, Pages 1039-1051

  Hersey, P ^a   Halliday, G M ^b   Farrelly, M L ^a   DeSilva, C ^c   Lett, M ^c   Menzies, S W ^c  

^a Oncology and Immunology Unit   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Clinical responses; Dendritic cells; Interleukin 2; Melanoma; Melanoma peptides; Vaccines

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 100; INFLUENZA VACCINE; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 3 A2; MELANOMA ANTIGEN A10; MELANOMA ANTIGEN NA17; MONOPHENOL MONOOXYGENASE; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CELL LYSATE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DEPRESSION; DIARRHEA; DISEASE ACTIVITY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; IMMATURITY; LETHARGY; LOG RANK TEST; LOW DRUG DOSE; MALAISE; MALE; MELANOMA; METASTASIS; NAUSEA; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; SENSITIZATION; SKIN TEST; TREATMENT OUTCOME; TREATMENT RESPONSE; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 42649091526     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0435-8     Document Type: Article

References (35)